Fresenius SE & Co. (OTCMKTS:FSNUY) Shares Gap Up – What’s Next?

Fresenius SE & Co. (OTCMKTS:FSNUY)’s share price gapped up before the market opened on Wednesday. The stock had previously closed at $12.56, but opened at $13.36. Fresenius SE & Co. shares last traded at $12.9075, with a volume of 13,854 shares changing hands.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on FSNUY. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Fresenius SE & Co. in a report on Thursday, August 6th. Morgan Stanley reissued an “overweight” rating on shares of Fresenius SE & Co. in a research report on Tuesday, July 21st. Three investment analysts have rated the stock with a Buy rating. According to MarketBeat, the company presently has an average rating of “Buy”.

Fresenius SE & Co. Stock Performance

The company has a debt-to-equity ratio of 0.41, a quick ratio of 0.97 and a current ratio of 1.28. The stock’s fifty day moving average is $12.98 and its two-hundred day moving average is $12.35. The firm has a market cap of $28.93 billion, a price-to-earnings ratio of 16.25 and a beta of 0.60.

Fresenius SE & Co. (OTCMKTS:FSNUY) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $0.24 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.01). Fresenius SE & Co. had a return on equity of 10.25% and a net margin of 6.67%. The business had revenue of $6.91 billion during the quarter, compared to the consensus estimate of $6.65 billion. On average, analysts expect that Fresenius SE & Co. will post 1.08 earnings per share for the current fiscal year.

Fresenius SE & Co. Company Profile

Fresenius SE & Co KGaA is a Germany-based global health care group that develops and provides products, services and technologies for hospitals, clinics and patients. The company’s activities are focused primarily on health care products and therapies, as well as the operation of hospitals and other medical facilities.

Fresenius Kabi, one of the company’s core businesses, supplies medicines and therapies for critically and chronically ill patients, including intravenous drugs, clinical nutrition, infusion therapies, medical devices and related services.